Gaelic Laboratories has agreed to acquire Athlone Laboratories in a move that consolidates two established Irish producers of beta-lactam antibiotics and strengthens domestic manufacturing capacity for oral and injectable penicillin-based products.

Ireland has become a central hub for pharmaceutical manufacturing thanks to its stable political environment and long-standing government support for the sector. The combination of two of the country’s best recognised beta-lactam manufacturers positions the enlarged business to expand output, streamline operations and reinforce its role in global antibiotic supply.

The companies have operated in complementary areas of the beta-lactam space for many years. Gaelic Laboratories manufactures a broad portfolio of beta-lactam products, while Athlone Laboratories focuses on oral-dose beta-lactam development and production. Bringing the organisations together is expected to support a wider product range, improved efficiencies and stronger supply chain integration.

Brian Morrissey, general manager of Gaelic Laboratories, said: “The deal is expected to deliver multiple financial and operational benefits, including cost savings through manufacturing consolidation, revenue growth and increased regulatory advantages.” He added that Athlone Laboratories’ established place in the beta-lactam supply chain makes it “a great match for Gaelic Labs” and that the merged business will “leverage many operational synergies”.

Gaelic Laboratories plans to retain personnel at the Athlone site, including the existing management team, to maintain business continuity. The company said the structure will allow a smooth transition for suppliers and customers while aligning processes and decision-making. Athlone’s senior leadership will now report to Morrissey, who will oversee both sites.

The enlarged company’s workforce has grown to around 120 people. Gaelic Laboratories said its long-standing commitment to supporting skilled jobs in Ireland will continue, and that several operational transition programmes are under way to ensure knowledge transfer and stability. Morrissey said: “We know that those people are the driving force behind our success.”

Both companies expect product supply and customer contracts to continue without disruption. The acquisition follows recent facility upgrades at Gaelic Laboratories, and investment is planned to expand manufacturing capacity across the two sites. The organisations will also align IT systems, compliance processes and quality infrastructure, with the aim of improving throughput and enabling greater supply chain resilience.

The combined portfolio of beta-lactam products is expected to provide customers with broader options supported by consolidated manufacturing expertise. Gaelic Laboratories said the integration will help optimise production processes, diversify product development and maintain reliable access to essential antibiotic products.